Related Experiment Videos
4-hydroxyandrostenedione--further clinical and extended endocrine observations
Abstract:
4-Hydroxyandrostenedione (4-OHA) was administered (250 mg intramuscularly 2-weekly) in a phase 2 clinical trial to 20 postmenopausal patients with advanced breast cancer, who had failed other endocrine therapy. Seven out of 18 assessable patients (39%) responded with minimal toxicity. Endocrine studies demonstrated that the drug produced significant initial falls in oestradiol and oestrone levels, but that these levels rose toward pretreatment levels as the study progressed. Sex hormone binding globulin (SHBG) levels gradually fell during the study suggesting that the drug has a minor degree of androgenic activity albeit of no clinical significance. There was a transient reduction of adrenal steroid levels, which remained however within the normal range. There were no symptoms of adrenal insufficiency.
Insights
This phase 2 trial found 4-hydroxyandrostenedione (4-OHA) effective in 39% of postmenopausal advanced breast cancer patients resistant to other therapies, with minimal toxicity observed during treatment.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Advanced breast cancer in postmenopausal women often necessitates endocrine therapy.
- Patients who fail initial endocrine treatments require alternative therapeutic strategies.
- 4-Hydroxyandrostenedione (4-OHA) is an investigational agent for endocrine-resistant breast cancer.
Purpose of the Study:
- To evaluate the efficacy and safety of 4-hydroxyandrostenedione (4-OHA) in postmenopausal women with advanced breast cancer.
- To assess the endocrine effects of 4-OHA, including its impact on hormone levels and adrenal function.
- To determine response rates and toxicity in patients who have progressed on prior endocrine therapies.
Main Methods:
- A phase 2 clinical trial was conducted involving 20 postmenopausal patients with advanced breast cancer.
- Patients received 4-hydroxyandrostenedione (4-OHA) at a dose of 250 mg intramuscularly every two weeks.
- Endocrine parameters, including oestradiol, oestrone, sex hormone binding globulin (SHBG), and adrenal steroid levels, were monitored throughout the study.
Main Results:
- Seven out of 18 assessable patients (39%) demonstrated a response to 4-OHA treatment.
- The treatment was associated with minimal toxicity.
- Initial significant reductions in oestradiol and oestrone were observed, with levels trending back towards baseline during the study.
- A gradual decrease in sex hormone binding globulin (SHBG) levels suggested minor androgenic activity.
- Transient reductions in adrenal steroid levels occurred but remained within normal limits, with no signs of adrenal insufficiency.
Conclusions:
- 4-Hydroxyandrostenedione (4-OHA) shows promising efficacy in a subset of postmenopausal patients with advanced breast cancer who have failed prior endocrine therapies.
- The drug is generally well-tolerated, exhibiting minimal toxicity.
- Endocrine monitoring indicates a complex hormonal modulation, including temporary suppression of oestrogen and minor androgenic effects, without clinically significant adrenal impairment.